{"id":"placebo-of-ir-tablet","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5836125","moleculeType":null,"molecularWeight":"347.42"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebo is an inert substance used as a control in clinical trials to establish baseline efficacy and safety of an investigational drug. Any observed effects are attributed to the placebo effect (psychological and contextual factors) rather than a specific molecular mechanism. Placebos are essential for blinded study designs to isolate the true therapeutic benefit of the active drug being tested.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:13.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control arm (Phase 3)"}]},"trialDetails":[{"nctId":"NCT05727189","phase":"PHASE1","title":"A Study of Idazoxan in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Terran Biosciences Australia Pty Ltd","startDate":"2023-02-14","conditions":"Healthy","enrollment":150},{"nctId":"NCT07266805","phase":"PHASE3","title":"Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency","status":"RECRUITING","sponsor":"Pharvaris Netherlands B.V.","startDate":"2025-10-16","conditions":"Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)","enrollment":32},{"nctId":"NCT06967857","phase":"PHASE2","title":"Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression","status":"RECRUITING","sponsor":"Prof. Dr. Frank Behrens","startDate":"2025-05-15","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder","enrollment":105},{"nctId":"NCT05081245","phase":"PHASE2","title":"ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MapLight Therapeutics","startDate":"2022-09-13","conditions":"Autism Spectrum Disorder","enrollment":150},{"nctId":"NCT06354088","phase":"PHASE1","title":"Human Models of Selective Insulin Resistance: Alpelisib, Part I","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-04-24","conditions":"Insulin Resistance, Prediabetic State, Overweight and Obesity","enrollment":32},{"nctId":"NCT06042855","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2023-09-05","conditions":"Covid19","enrollment":3214},{"nctId":"NCT04594694","phase":"PHASE2","title":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2019-10-02","conditions":"Primary Biliary Cholangitis","enrollment":75},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT05239468","phase":"PHASE2","title":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC","status":"COMPLETED","sponsor":"Intercept Pharmaceuticals","startDate":"2022-03-21","conditions":"Primary Biliary Cholangitis","enrollment":72},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT04996264","phase":"PHASE2","title":"Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite","status":"COMPLETED","sponsor":"Ophirex, Inc.","startDate":"2021-08-15","conditions":"Snakebites, Envenoming, Envenoming, Snake","enrollment":95},{"nctId":"NCT04865536","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2021-02-03","conditions":"Tuberculosis, Tuberculosis, Pulmonary","enrollment":28},{"nctId":"NCT06878833","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder","status":"WITHDRAWN","sponsor":"Lyndra Inc.","startDate":"2025-04-18","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""},{"nctId":"NCT06708611","phase":"PHASE4","title":"A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs","status":"TERMINATED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-01-15","conditions":"Heart Failure","enrollment":5},{"nctId":"NCT01199133","phase":"PHASE3","title":"Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children","status":"TERMINATED","sponsor":"Stallergenes Greer","startDate":"2009-10","conditions":"Allergic Rhinitis Due to Dust Mite","enrollment":471},{"nctId":"NCT01527188","phase":"PHASE2","title":"Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2010-12-08","conditions":"Allergic Rhinitis Due to House Dust Mite","enrollment":355},{"nctId":"NCT05062200","phase":"PHASE1","title":"A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-10-25","conditions":"Healthy","enrollment":36},{"nctId":"NCT01919554","phase":"PHASE1","title":"Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2013-07","conditions":"Allergic Rhinitis Due to House Dust Mite","enrollment":37},{"nctId":"NCT03758612","phase":"PHASE1","title":"A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2019-01-16","conditions":"Tuberculosis, Tuberculosis, Pulmonary","enrollment":86},{"nctId":"NCT05567354","phase":"PHASE1","title":"A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2022-06-10","conditions":"Recreational Drug Use","enrollment":27},{"nctId":"NCT06487845","phase":"PHASE1","title":"A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-07-04","conditions":"Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy, Healthy Volunteers","enrollment":24},{"nctId":"NCT05571345","phase":"PHASE1","title":"A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2022-10-05","conditions":"Recreational Drug Use","enrollment":32},{"nctId":"NCT03642964","phase":"PHASE2","title":"A Study in Patients With Major Depressive Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chase Therapeutics Corporation","startDate":"2018-09-10","conditions":"Major Depressive Disorder (MDD)","enrollment":24},{"nctId":"NCT03785756","phase":"PHASE3","title":"Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars","status":"COMPLETED","sponsor":"Reckitt Benckiser Healthcare (UK) Limited","startDate":"2019-04-29","conditions":"Pain","enrollment":280},{"nctId":"NCT04310579","phase":"PHASE1","title":"Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-06-15","conditions":"Hypercapnia, Ventilatory Depression","enrollment":55},{"nctId":"NCT03507413","phase":"PHASE2, PHASE3","title":"Metformin Therapy in Non-diabetic AAA Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2018-09-26","conditions":"Abdominal Aortic Aneurysm","enrollment":170},{"nctId":"NCT00226395","phase":"PHASE3","title":"Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2004-09","conditions":"Acute Pain","enrollment":320},{"nctId":"NCT05716854","phase":"PHASE1","title":"Electrophysiological Effects of Potential QT Prolonging Drugs","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2023-03-21","conditions":"Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics","enrollment":44},{"nctId":"NCT03515044","phase":"PHASE2","title":"Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2018-09-13","conditions":"Overt Hepatic Encephalopathy","enrollment":71},{"nctId":"NCT04854512","phase":"PHASE3","title":"Investigational Study of Delayed Release Metformin","status":"SUSPENDED","sponsor":"Anji Pharma","startDate":"2021-05-18","conditions":"Diabetes Mellitus, Type 2","enrollment":675},{"nctId":"NCT04862741","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Landos Biopharma Inc.","startDate":"2021-05-05","conditions":"Ulcerative Colitis","enrollment":39},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT04567524","phase":"PHASE2","title":"A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules","status":"COMPLETED","sponsor":"Lyndra Inc.","startDate":"2020-08-13","conditions":"Schizophrenia Schizoaffective","enrollment":34},{"nctId":"NCT04968522","phase":"PHASE4","title":"FASST - Fetal Alcohol Spectrum Stimulant Trial","status":"UNKNOWN","sponsor":"Monash Medical Centre","startDate":"2022-02-14","conditions":"Fetal Alcohol Spectrum Disorders","enrollment":20},{"nctId":"NCT04808531","phase":"PHASE3","title":"NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers","status":"UNKNOWN","sponsor":"Medlab Clinical","startDate":"2023-11","conditions":"Cancer Related Pain","enrollment":360},{"nctId":"NCT02487108","phase":"PHASE3","title":"Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-08-11","conditions":"Pain","enrollment":569},{"nctId":"NCT01473108","phase":"PHASE1","title":"Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-03-29","conditions":"Clinical Pharmacology","enrollment":67},{"nctId":"NCT04647903","phase":"PHASE1","title":"Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)","status":"COMPLETED","sponsor":"Vallon Pharmaceuticals, Inc.","startDate":"2020-10-05","conditions":"ADHD, Narcolepsy","enrollment":55},{"nctId":"NCT05128175","phase":"PHASE1","title":"Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions","status":"UNKNOWN","sponsor":"Shanghai WD Pharmaceutical Co., Ltd.","startDate":"2021-10-29","conditions":"Parkinson Disease","enrollment":15},{"nctId":"NCT05118958","phase":"PHASE1","title":"Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations","status":"COMPLETED","sponsor":"KalVista Pharmaceuticals, Ltd.","startDate":"2020-05-19","conditions":"Hereditary Angioedema","enrollment":37},{"nctId":"NCT04575610","phase":"PHASE2","title":"IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)","status":"TERMINATED","sponsor":"Yale University","startDate":"2020-11-27","conditions":"COVID-19","enrollment":7},{"nctId":"NCT03757559","phase":"PHASE1","title":"A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2013-04-15","conditions":"Abuse, Drug","enrollment":226},{"nctId":"NCT04933799","phase":"PHASE2","title":"IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.","status":"UNKNOWN","sponsor":"Giovanni Franchin, M.D, Ph.D","startDate":"2021-01-06","conditions":"COVID-19 Pneumonia","enrollment":68},{"nctId":"NCT02799758","phase":"PHASE3","title":"Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia","status":"WITHDRAWN","sponsor":"Kowa Research Institute, Inc.","startDate":"2016-02","conditions":"Hyperlipidemia, Dyslipidemia","enrollment":""},{"nctId":"NCT02504671","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-23","conditions":"Arthritis, Rheumatoid","enrollment":222},{"nctId":"NCT03547583","phase":"PHASE2","title":"Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-15","conditions":"Chronic Heart Failure With Preserved Ejection Fraction","enrollment":789},{"nctId":"NCT01721317","phase":"PHASE4","title":"Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-12-19","conditions":"Seizures","enrollment":6},{"nctId":"NCT03128320","phase":"PHASE2","title":"The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-05-25","conditions":"Diabetic Foot","enrollment":23},{"nctId":"NCT03800472","phase":"PHASE1","title":"A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2019-01-15","conditions":"Healthy","enrollment":95},{"nctId":"NCT02240459","phase":"PHASE2","title":"A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-08","conditions":"Overactive Bladder, Mild Cognitive Impairment","enrollment":47},{"nctId":"NCT03187795","phase":"PHASE2","title":"Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2019-04-03","conditions":"Spinal Cord Injuries, Urinary Bladder, Neurogenic","enrollment":62},{"nctId":"NCT00914290","phase":"PHASE2","title":"A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2009-04","conditions":"Spasticity, Multiple Sclerosis","enrollment":23},{"nctId":"NCT00279825","phase":"PHASE2","title":"Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2006-01","conditions":"Idiopathic Parkinson's Disease","enrollment":16},{"nctId":"NCT00253084","phase":"PHASE2","title":"Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2005-11","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT01904409","phase":"PHASE2","title":"Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-06","conditions":"Liver Cirrhosis","enrollment":420},{"nctId":"NCT02443805","phase":"PHASE3","title":"Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2015-09-29","conditions":"Rhinitis, Allergic, Perennial, House Dust Mite Allergy","enrollment":1607},{"nctId":"NCT02605434","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2016-03","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT00256854","phase":"PHASE3","title":"Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-14","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":135},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT03768024","phase":"PHASE1","title":"A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2007-06-21","conditions":"Pain, Acute Pain","enrollment":76},{"nctId":"NCT03765346","phase":"PHASE1","title":"A Comparison of How Likely it is That Different Tablets of Oxycodone Will be Broken up and Snorted by Adults Who Sometimes Take Drugs for Pleasure","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2018-07-24","conditions":"Substance Abuse","enrollment":123},{"nctId":"NCT01451827","phase":"PHASE2","title":"8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":178},{"nctId":"NCT00973973","phase":"PHASE2","title":"Efficacy and Safety Study of Elagolix in Women With Endometriosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2009-10-12","conditions":"Endometriosis, Pain","enrollment":137},{"nctId":"NCT02307864","phase":"PHASE1","title":"Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2014-12-04","conditions":"Healthy","enrollment":68},{"nctId":"NCT01648101","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-08-29","conditions":"Epilepsy","enrollment":76},{"nctId":"NCT00996944","phase":"PHASE2","title":"Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-30","conditions":"Restless Legs Syndrome","enrollment":34},{"nctId":"NCT00146640","phase":"PHASE3","title":"Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-08-31","conditions":"Rheumatoid Arthritis","enrollment":288},{"nctId":"NCT03239353","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects","status":"COMPLETED","sponsor":"Aucta Pharmaceuticals, Inc","startDate":"2017-10-20","conditions":"HBV","enrollment":40},{"nctId":"NCT01210560","phase":"PHASE2","title":"Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":25},{"nctId":"NCT02982161","phase":"PHASE3","title":"Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib).","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2016-12-28","conditions":"Acute Pain","enrollment":818},{"nctId":"NCT02526524","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2015-09","conditions":"Type 2 Diabetes Mellitus","enrollment":571},{"nctId":"NCT03478475","phase":"NA","title":"Vitamin D Supplementation and and Glycemic Indexes","status":"COMPLETED","sponsor":"Université d'Auvergne","startDate":"2015-07-02","conditions":"Deficiency, Vitamin D, Insulin Resistance","enrollment":115},{"nctId":"NCT03475862","phase":"PHASE1","title":"Nasal Human Abuse Potential of PTI-821","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2017-05-15","conditions":"Opioid Abuse Nondependent","enrollment":38},{"nctId":"NCT02273050","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":1136},{"nctId":"NCT02452515","phase":"PHASE2","title":"A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-07","conditions":"Heart Failure","enrollment":49},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT01775189","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Healthy","enrollment":45},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01871285","phase":"PHASE2","title":"Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film","status":"COMPLETED","sponsor":"BioDelivery Sciences International","startDate":"2013-06","conditions":"Pain","enrollment":39},{"nctId":"NCT02063854","phase":"PHASE2, PHASE3","title":"A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Involutional Osteoporosis","enrollment":871},{"nctId":"NCT00866294","phase":"PHASE3","title":"Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Depressive Disorder","enrollment":416},{"nctId":"NCT02139046","phase":"PHASE3","title":"Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-04","conditions":"Gout","enrollment":1790},{"nctId":"NCT02128490","phase":"PHASE2","title":"Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05","conditions":"Gout, Moderate Renal Impairment","enrollment":189},{"nctId":"NCT01902550","phase":"PHASE1","title":"A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2013-07","conditions":"Healthy","enrollment":""},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT00409409","phase":"PHASE3","title":"Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2006-12","conditions":"Allergy","enrollment":278},{"nctId":"NCT00418379","phase":"PHASE3","title":"Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2006-12","conditions":"Allergy","enrollment":633},{"nctId":"NCT00803244","phase":"PHASE3","title":"Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2009-01","conditions":"Primary Disease","enrollment":381},{"nctId":"NCT00619827","phase":"PHASE1","title":"Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2007-09","conditions":"Seasonal Allergic Rhinitis","enrollment":89},{"nctId":"NCT00367640","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2004-11","conditions":"Allergy","enrollment":628},{"nctId":"NCT00955825","phase":"PHASE3","title":"Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2008-10","conditions":"Allergic Rhinitis Due to Grass Pollens","enrollment":473},{"nctId":"NCT00674700","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2007-10","conditions":"Allergic Rhinitis","enrollment":509},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT00652093","phase":"PHASE4","title":"Lumbar Stenosis Outcomes Research II","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2008-03","conditions":"Lumbar Spinal Stenosis","enrollment":24},{"nctId":"NCT00855660","phase":"PHASE1","title":"Effect of Riociguat on Bone Metabolism","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03","conditions":"Pharmacology, Clinical","enrollment":17},{"nctId":"NCT01389284","phase":"PHASE3","title":"Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06","conditions":"Pain, Postoperative","enrollment":300},{"nctId":"NCT01332942","phase":"PHASE1","title":"Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-04","conditions":"Anemia","enrollment":44},{"nctId":"NCT00885378","phase":"PHASE3","title":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT00327015","phase":"PHASE3","title":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Diabetes","enrollment":1306}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of IR tablet","genericName":"Placebo of IR tablet","companyName":"Reckitt Benckiser Healthcare (UK) Limited","companyId":"reckitt-benckiser-healthcare-uk-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Clinical trial control arm (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}